Reuters highlights Medline’s blockbuster U.S. IPO filing, which could value the healthcare giant at up to $50 billion. Commenting on the deal, IPOX® Research Associate Lukas Muehlbauer said the offering “signals that the IPO market remains wide open despite the shutdown” and will serve as a key test of investor confidence heading into 2026. Medline’s listing, expected to be one of the year’s largest, underscores renewed strength in the U.S. IPO market after several years of subdued activity.

Reuters features IPOX® Research Associate Lukas Muehlbauer commenting on the biotech IPO rebound following MapLight Therapeutics’ $787 million Nasdaq debut. Muehlbauer notes that while the market is “slowly thawing,” many 2021–2023 listings still trade below offer prices, creating challenges for early-stage biotech firms seeking investor confidence.

Earnings season is in full swing, with U.S. banks kicking off the reporting cycle and key IPOX® Index constituents set to follow. Next week will feature major updates from leading firms across the IPOX® 100 U.S., IPOX® Europe, and IPOX® International indexes — including GE Vernova, IBM, Nextracker, MilDef, Porsche, and CATL — offering valuable insight into global sector performance and momentum across IPOX® portfolios.

In a Reuters article on Navan’s planned $6.45 billion U.S. IPO, IPOX® CEO Josef Schuster commented on the impact of the ongoing U.S. government shutdown on IPO sentiment. Schuster noted that while optimism remains, “heightened volatility” and regulatory delays may weigh on demand, urging issuers to remain flexible with offering terms.

In a Reuters feature on how companies are navigating IPO plans during the U.S. government shutdown, IPOX® Research Associate Lukas Muehlbauer explained why biotech firms like MapLight are seizing this favorable market window despite regulatory delays. Muehlbauer noted that MapLight aims to get ahead of the SEC backlog, though the 20-day pricing lock limits flexibility. He added that biotech firms’ urgent funding needs make them prime candidates for this route.

Reuters reports that MapLight Therapeutics is targeting a $704.3 million valuation in its U.S. IPO, reflecting renewed investor appetite for biotech offerings. IPOX® CEO Josef Schuster described the move as “opportunistic”, citing the strong market climate for IPOs and heightened M&A activity in the sector. Schuster added that MapLight’s promising drug candidates and market momentum are likely to attract significant investor interest.

In a recent Reuters article, IPOX® CEO Josef Schuster commented on Cerebras Systems’ decision to withdraw its planned U.S. IPO, following the company’s $1.1 billion funding round. Schuster noted the move was “no surprise” given the recent capital raise, emphasizing it was a strategic decision rather than a reflection of market weakness, adding that U.S. IPO sentiment remains exceptionally strong amid renewed investor enthusiasm for AI-related offerings.

A U.S. government shutdown has halted SEC IPO processing, creating uncertainty just as the market was rebounding. While some deals may face delays, IPOX® research analyst Lukas Muehlbauer emphasized that strong investor demand and inflows into IPO-focused funds should sustain momentum once operations resume. “The best after-market performance in years will continue to lure companies to the market,” he noted.

Education provider Phoenix Education Partners, owner of the University of Phoenix, is targeting a valuation of up to $1.17B in its planned U.S. IPO. Backed by Apollo Global and Vistria Group, the firm seeks to raise $140.3M with shares priced between $31–33, listing on the NYSE under "PXED." IPOX® CEO Josef Schuster noted strong sentiment for U.S. IPOs, highlighting differences in PE-backed deals. The offering reflects renewed sponsor-led listing momentum.

Wealthfront has filed for a U.S. IPO after reporting $308.9 million in 2025 revenue, up from $216.7 million a year earlier. Commenting on the filing, IPOX® CEO Josef Schuster noted that the U.S. IPO market remains “extremely healthy” going into Q4 but cautioned that investor appetite may be tested if pricing is too aggressive, citing recent post-listing performance of Chime and eToro.

Reuters highlights IPOX® CEO Josef Schuster’s commentary on Alliance Laundry’s planned $4.34 billion IPO. Backed by BDT & MSD Partners, the company aims to raise up to $751 million on the NYSE under “ALH.” Schuster noted that the inclusion of PE-backed firms broadens U.S. IPO deal flow and that cornerstone investor demand underscores the IPO’s medium- to long-term appeal.

Electric aircraft maker Beta Technologies has filed for a U.S. IPO, aiming to trade on the NYSE under the ticker BETA. In coverage by Reuters, Kat Liu, Vice President at IPOX®, noted: “Beta's IPO plays into two narratives that are resonating with investors: the long-term electrification trend and renewed appetite for selective growth stories.” The listing highlights growing investor interest in sustainable aviation and clean mobility solutions.

Ethos Technologies filed for a U.S. IPO after reporting a 55% revenue surge in the first half of 2025, with net income rising to $30.7 million. The insurer joins a wave of peers tapping strong demand for listings. While some, like Accelerant and Slide, trade below offer prices, others have fared better. IPOX® Vice President Kat Liu noted investors will closely watch outcomes to gauge sustainable performance.

Bloomberg reports a strong revival in the U.S. IPO market, with newly listed companies up 41% in 2025, far outpacing the S&P 500. Large deals have been particularly lucrative, driving investor interest back to IPO-linked products. The First Trust US Equity Opportunities ETF (FPX), which tracks the IPOX® 100 U.S. Index, has surged 37% year-to-date. Bloomberg notes fresh inflows and rising optimism for innovation-driven companies entering public markets.

Bloomberg highlights the potential revival of Canada’s IPO market with Brookfield-backed Rockpoint Gas Storage’s planned Toronto listing. IPOX® VP Kat Liu, noted that Rockpoint’s performance could pave the way for additional carve-outs: “Based on how well they do with Rockpoint, there are a lot more portfolio companies that can easily go.” Investors are watching closely as confidence builds for renewed Canadian deal activity.

Neptune Insurance is targeting a $2.76 billion valuation in its upcoming U.S. IPO, Reuters reports. IPOX® Vice President Kat Liu noted the company’s strong growth story and highlighted climate change as a key driver of future demand: “If Neptune can capture share beyond NFIP and retain policies effectively, the growth opportunity could bolster IPO prospects.” The insurer will list on the NYSE under ticker “NP.”

Pattern Group’s $2.4 billion Nasdaq debut drew attention as shares slipped 3.6% on opening day, Reuters reported. Commenting on the IPO, IPOX® Associate Muehlbauer noted that investors remain selective, rewarding strong fundamentals while others face tougher receptions. He added that Pattern’s reliance on Amazon poses risks amid shifting platform rules, with broader trade policy changes creating added challenges for cross-border sellers.

SMG Swiss Marketplace Group surged 8.7% above its offering price in its Zurich debut, signaling renewed strength in Europe’s IPO market. IPOX® Associate Lukas Muehlbauer noted the aftermarket lift was “to be expected given there’s a scarcity of large deals in Europe,” adding that strong performance boosts investor confidence.

IPO activity is surging again, with more than 150 companies going public this year and strong first-day gains fueling renewed investor interest. Yet volatility and high valuations remain challenges. In Barron’s, IPOX® Founder and CEO Josef Schuster highlighted our disciplined, long-term approach to IPO investing.

Bloomberg’s “IPOs Resurrect” notes a vigorous reopening of the U.S. new-issue window and highlights the IPOX® 100 U.S. Index’s leadership. The IPOX-100 of recently floated shares has “massively outperformed” since April’s post-“Liberation Day” rally, signaling revived risk appetite and encouraging more listings. With AI, crypto and fintech names accelerating, IPO breadth and pricing are improving, even as valuations normalize versus peak private rounds.